• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Trevi Therapeutics Inc. (Amendment)

    2/14/24 8:47:01 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    SC 13G/A 1 tm246235d26_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*

      

    Trevi Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    89532M101

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 89532M101 Page 2 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 3 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 4 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 5 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 6 of 17

     

       
    1.

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    PN

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 7 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management II, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 8 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 9 of 17

     

       
    1.

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    OO

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 10 of 17

     

       
    1.

    Name of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 11 of 17

     

       
    1.

    Name of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.

    SEC USE ONLY

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    6,707,5642

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    6,707,5642

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,707,5642

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    9.99%3

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    1Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

    3This percentage is calculated based upon the sum of (i) 63,857,622 shares outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023 and (ii) 3,285,167 shares issuable upon the exercise of the Warrants described in Footnote 2 above.

     

     

     

     

    CUSIP No. 89532M101 Page 12 of 17

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Trevi Therapeutics, Inc.

     

    Item 1.

     

    (a)Name of Issuer

     

    Trevi Therapeutics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    195 Church Street, 14th Floor

    New Haven, Connecticut 06510

     

    Item 2.

     

    (a)Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.
    VHCP Co-Investment Holdings II, LLC
    Venrock Healthcare Capital Partners III, L.P.
    VHCP Co-Investment Holdings III, LLC
    Venrock Healthcare Capital Partners EG, L.P.
    VHCP Management II, LLC
    VHCP Management III, LLC
    VHCP Management EG, LLC
    Nimish Shah
    Bong Koh

     

    (b)Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

    (c)Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

     

     

     

    CUSIP No. 89532M101 Page 13 of 17

     

    (d)Title of Class of Securities

     

    Common Stock, par value $0.001 per share

     

    (e)CUSIP Number

     

    89532M101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

    (a)Amount Beneficially Owned as of December 31, 2023:

     

    Venrock Healthcare Capital Partners II, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings II, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners III, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings III, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners EG, L.P. 6,707,564 (1)
    VHCP Management II, LLC 6,707,564 (1)
    VHCP Management III, LLC 6,707,564 (1)
    VHCP Management EG, LLC 6,707,564 (1)
    Nimish Shah 6,707,564 (1)
    Bong Koh 6,707,564 (1)

     

    (b)Percent of Class as of December 31, 2023:

     

    Venrock Healthcare Capital Partners II, L.P. 9.99%
    VHCP Co-Investment Holdings II, LLC 9.99%
    Venrock Healthcare Capital Partners III, L.P. 9.99%
    VHCP Co-Investment Holdings III, LLC 9.99%
    Venrock Healthcare Capital Partners EG, L.P. 9.99%
    VHCP Management II, LLC 9.99%
    VHCP Management III, LLC 9.99%
    VHCP Management EG, LLC 9.99%
    Nimish Shah 9.99%
    Bong Koh 9.99%

     

    (c)Number of shares as to which the person has, as of December 31, 2023:

     

    (i)Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P. 0
    VHCP Co-Investment Holdings II, LLC 0
    Venrock Healthcare Capital Partners III, L.P. 0
    VHCP Co-Investment Holdings III, LLC 0
    Venrock Healthcare Capital Partners EG, L.P. 0
    VHCP Management II, LLC 0
    VHCP Management III, LLC 0
    VHCP Management EG, LLC 0
    Nimish Shah 0
    Bong Koh 0

     

     

     

     

    CUSIP No. 89532M101 Page 14 of 17

     

    (ii)Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings II, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners III, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings III, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners EG, L.P. 6,707,564 (1)
    VHCP Management II, LLC 6,707,564 (1)
    VHCP Management III, LLC 6,707,564 (1)
    VHCP Management EG, LLC 6,707,564 (1)
    Nimish Shah 6,707,564 (1)
    Bong Koh 6,707,564 (1)

     

    (iii)Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P. 0
    VHCP Co-Investment Holdings II, LLC 0
    Venrock Healthcare Capital Partners III, L.P. 0
    VHCP Co-Investment Holdings III, LLC 0
    Venrock Healthcare Capital Partners EG, L.P. 0
    VHCP Management II, LLC 0
    VHCP Management III, LLC 0
    VHCP Management EG, LLC 0
    Nimish Shah 0
    Bong Koh 0

     

    (iv)Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings II, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners III, L.P. 6,707,564 (1)
    VHCP Co-Investment Holdings III, LLC 6,707,564 (1)
    Venrock Healthcare Capital Partners EG, L.P. 6,707,564 (1)
    VHCP Management II, LLC 6,707,564 (1)
    VHCP Management III, LLC 6,707,564 (1)
    VHCP Management EG, LLC 6,707,564 (1)
    Nimish Shah 6,707,564 (1)
    Bong Koh 6,707,564 (1)

     

    (1)Consists of (i) 547,153 shares and 357,755 shares issuable upon the exercise of immediately exercisable pre-funded warrants (“Warrants”) held by Venrock Healthcare Capital Partners II, L.P., (ii) 221,711 shares and 144,970 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings II, LLC, (iii) 1,184,704 shares and 1,052,442 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners III, L.P., (iv) 118,534 shares and 105,299 shares issuable upon the exercise of Warrants held by VHCP Co-Investment Holdings III, LLC and (v) 1,350,295 shares and 1,624,700 shares issuable upon the exercise of Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers in the preceding sentence represent the maximum number of shares of common stock issuable upon exercise of the Warrants held by the Reporting Persons as a result of the beneficial ownership provision described in the following sentence. Under the terms of the Warrants, the Issuer may not effect the exercise of any such Warrant, and a holder will not be entitled to exercise any portion of such Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates and other attribution parties) would exceed 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise.

     

     

     

     

    CUSIP No. 89532M101 Page 15 of 17

     

        VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

      

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    CUSIP No. 89532M101 Page 16 of 17

     


    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   By: /s/ Sherman G. Souther
    Its: General Partner     Name:   Sherman G. Souther
          Its:   Authorized Signatory
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
             
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         

    Nimish Shah   Bong Koh
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
          Sherman G. Souther, as attorney-in-fact         Sherman G. Souther, as attorney-in-fact

     

     

     

     

    CUSIP No. 89532M101 Page 17 of 17

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit B to Schedule 13G filed on April 21, 2022)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on April 21, 2022)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit B to Schedule 13G filed on April 21, 2022)

     

     

     

    Get the next $TRVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    8/30/2024$6.00Buy
    H.C. Wainwright
    8/30/2024$9.00Outperform
    Raymond James
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/12/2023$6.00Buy
    B. Riley Securities
    More analyst ratings

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Trevi Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously

      3/10/25 8:08:41 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Trevi Therapeutics with a new price target

      Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $25.00 from $8.00 previously

      3/10/25 7:49:08 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Trevi Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.50 from $6.00 previously

      12/12/24 12:56:25 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

      NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

      9/30/24 5:30:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

      Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d

      4/2/24 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Sciascia Thomas exercised 2,631 shares at a strike of $1.43 and sold $17,365 worth of shares (2,631 units at $6.60) (SEC Form 4)

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/26/25 4:30:14 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Good Jennifer L exercised 5,263 shares at a strike of $1.43 and sold $34,625 worth of shares (5,263 units at $6.58) (SEC Form 4)

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/25/25 4:30:04 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Sciascia Thomas

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      3/12/25 4:00:07 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Trevi Therapeutics Inc.

      10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)

      5/8/25 4:16:35 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

      5/8/25 4:12:52 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Trevi Therapeutics Inc.

      DEFA14A - Trevi Therapeutics, Inc. (0001563880) (Filer)

      4/29/25 11:30:18 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Financials

    Live finance-specific insights

    See more
    • Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)

      5/8/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

      Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2025. www.trevith

      5/1/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

      Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in IPF patients with chronic cough in February 2025, with topline data expected in the second quarter of 2025 Announced positive outcome from sample size re-estimation in the Phase 2b CORAL trial, resulting in no change to study sample size Ended 2024 with $107.6 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Managemen

      3/18/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)

      5/8/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

      Conference call and webcast to be held at 4:30 p.m. ET  NEW HAVEN, Conn., May 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) or refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, May 8, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2025. www.trevith

      5/1/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Participate in Upcoming April Investor Conferences

      NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">

      4/3/25 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/14/24 5:51:58 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/13/24 4:30:24 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

      SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/8/24 6:57:55 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care